The efficacy of bronchodilator nebuliser solutions may be influenced by the presence of preservatives. In a double blind, randomised, crossover study the effect of preservatives in determining the airway responses to 5 mg of terbutaline was studied in a group of 21 atopic asthmatic patients. The presence of preservatives affected neither the bronchodilator action of terbutaline nor its protection against bronchoconstriction induced by histamine. (Thorax 1993;48:566- The presence of preservatives in bronchodilator nebuliser solutions may cause bronchoconstriction or diminish the effectiveness of the drug constituents.' Although paradoxical bronchoconstriction has not been reported with terbutaline nebuliser solution, this formulation contains two preservatives-EDTA and chlorbutol-both of which have the capacity to cause bronchoconstriction.3 A preservative free formulation of terbutaline nebuliser solution has recently been introduced as unit dose vials, each 2 ml vial containing 5 mg terbutaline. In this study we have compared the efficacy of these two formulations (with and without preservatives) by examining their effects on airway calibre and histamine induced bronchoconstriction in a group of atopic asthmatic subjects.
The presence of preservatives in bronchodilator nebuliser solutions may cause bronchoconstriction or diminish the effectiveness of the drug constituents.' Although paradoxical bronchoconstriction has not been reported with terbutaline nebuliser solution, this formulation contains two preservatives-EDTA and chlorbutol-both of which have the capacity to cause bronchoconstriction.3 A preservative free formulation of terbutaline nebuliser solution has recently been introduced as unit dose vials, each 2 ml vial containing 5 mg terbutaline. In this study we have compared the efficacy of these two formulations (with and without preservatives) by examining their effects on airway calibre and histamine induced bronchoconstriction in a group of atopic asthmatic subjects.
Methods

SUBJECTS
Twenty one non-smoking patients (16 men) of mean (SE) age 35-2 (2 6) years with mild to moderate atopic asthma were studied. They had a mean (SE) baseline forced expiratory volume in one second (FEV,) of 1 92 (0.13) 1 or 59-2% (2-5%) predicted and were bronchial hyperresponsive with a provocation concentration of histamine causing a 20% fall in FEV, (PC,O) which ranged from 0-06 to 7-2 mg/ml (geometric mean 0-4 mg/ml). They all received regular inhaled corticosteroids and inhaled A3 agonists on demand.
Informed consent was obtained from each patient and the study was approved by the hospital ethical committee.
STUDY DESIGN
Subjects attended the laboratory at the same time of day on four separate occasions at least 48 hours apart. At each visit inhaled bronchodilators were withheld for 12 hours and inhaled steroid for 24 hours. Baseline FEV, was measured on each visit by a dry wedge spirometer (Vitalograph, Buckingham, UK). On the first visit this was followed by a histamine concentration-response study4 and skin prick tests to assess the degree of non-specific airway responsiveness and atopic state. On subsequent visits one of the three 2 ml solutions-preservative free terbutaline (PFT, 2-5 mg/ml), preservative containing terbutaline (PT, 0 5 ml of 10 mg/ml solution + 1-5 ml saline), or placebo (2 ml saline)-was inhaled in a random, double blind fashion via a face mask attached to a Hudson nebuliser driven by oxygen at a flow rate of 8 I/min. The inhalation was continued until nebulisation to dryness was achieved which generally took about seven minutes. FEV, was measured immediately and at 2, 5, 10, 15, and 30 minutes after nebulisation. This was then followed by a histamine concentration-response study. DATA 
ANALYSIS
The airway response for the two formulations of terbutaline solution and placebo was determined by comparing the maximum and minimum values of FEV, achieved, the areas under the FEV,-time response curves (AUC) calculated by trapezoid integration, and the values of histamine PC,0 obtained after the nebulised solutions. Two way analysis of variance was used to compare baseline FEV, values and the four indices of airway response between visits 2, 3, and 4. Any significance was further sought by the Newman Keuls' procedure. Least squares linear regression analysis was used to investigate the relationships between the bronchodilator effect of the active drugs and their ability to protect against histamine provoked bronchoconstric- Effect ofpreservative on the efficacy of terbutaline nebuliser solution in atopic asthma tion, and between this and baseline histam airway responsiveness.
Results
All subjects completed the study. There N no significant difference between basel FEV, on all treatment days; FEV, lel before histamine challenge on the place day was, however, significantly lower than both active treatment days, but values these latter days were not different ( in cant bronchoconstriction (more than 6% fall in FEV,) after inhalation of either preparation of terbutaline. Bronchial responsiveness to histamine was 35)* significantly reduced after inhalation of PFT or PT compared with that after placebo so)* (table 2) . Expressed as concentration ratios b)* with placebo, PFT and PT afforded a geometric mean protection of the airways of 4-6 (range 0-4-51) fold and 3-1 (04-27-2) fold respectively against bronchoconstriction provoked by histamine. Although there was a trend for a greater protection with PFT than PT, this was not significant (table 2) . No significant correlation was observed between the line histamine concentration ratio and the degree of bronchodilatation after inhalation of either preparation, or between the former and baseline histamine responsiveness. A significant correlation was found, however, between the was ability of the two preparations of terbutaline line to protect against histamine induced bronchovels constriction (r = 0 49, p < 0*05) ebo on on Discussion ).
In this study we have shown that the presence of of preservatives in terbutaline nebuliser soluon-tion does not appear to influence its effects as on the asthmatic airways, whether assessed as or bronchodilatation or as protection against itor histamine provoked bronchoconstriction. Our !ast data are in accord with the absence of any nce report of paradoxical bronchoconstriction s of provoked by nebulised terbutaline. The ig). apparent lack of effect of these preservatives lifi-could be related to their relatively weak bronchoconstrictor action: indeed bronchoconstriction did not occur in a group of asthmatic subjects after inhalation of chlorbutol.5
The ability to protect against a bronchoconstrictor agonist may be a more sensitive means of comparing the efficacy of broncho- Laryngoscopy revealed paresis of the left vocal cord and chest radiography showed enlargement of the aortic knuckle with tracheal deviation suggesting an aortic dissection. Computed tomography of the mediastinum revealed a mass which extended from the aortic knuckle down to the bifurcation of the trachea (fig 1) . Magnetic resonance imaging showed a mass extending from the carina to 3 cm above the aortic arch which suggested a lymphoma or thymoma. An aneurysm of the aorta was ruled out by these imaging procedures.
In order to identify the nature of this mass, exploratory thoracotomy was planned. Coronary angiography performed before thoracotomy showed progression of his coronary artery disease so coronary artery bypass surgery was planned for the same operation. Further preoperative examinations such as bronchoscopy, carotid artery sonography, bone scan, and angiography of the aortic arch showed nothing remarkable. 
